Q-omics provides the consensus-scored MTATP6P20 profile across patient tissues and cancer cell-line models. MTATP6P20 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, MTATP6P20 is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, MTATP6P20 RNA expression shows 6,318 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ESCA, BRCA, and STAD as cancer lineages where MTATP6P20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTATP6P20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTATP6P20 survival associations across molecular data types. MTATP6P20 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTATP6P20 RNA expression–survival associations across cancer types. High MTATP6P20 expression shows unfavorable associations in ESCA, PCPG, LGG and OV, but favorable associations in LUAD and UCS. The ESCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .008). Together, the overview and detailed table identify ESCA as the clearest survival context for MTATP6P20 RNA expression.
This table summarizes MTATP6P20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MTATP6P20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTATP6P20 shows lower tumor expression in BRCA, READ, LUAD and LUSC. The BRCA box plot shows higher MTATP6P20 RNA expression in normal versus tumor tissue (log2 FC = −0.044, t-test p = .009).
This table shows molecular features associated with MTATP6P20 in patient tissues and cancer cell lines. In patient samples, MTATP6P20 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
